Add BrightSurf on Google Email

Living bandage accelerates healing across multiple wound types

Researchers have developed a cell-based delivery platform that uses encapsulated engineered cells to secrete cytokines directly within the wound environment, supporting accelerated wound healing in rodent and porcine excisional wound models. The approach is designed to maintain therapeutic levels of signaling molecules at the wound site.

SourceRice University·JournalNature Biomedical Engineering·TypeExperimental study·DateMay 27, 2026

First-in-human trial demonstrates promise of implantable cytokine factories for ovarian cancer

A first-in-human trial demonstrates the potential of implantable cytokine factories for treating ovarian cancer, showing a favorable safety profile and encouraging disease stabilization in patients. The therapy successfully activated key immune cells without expanding regulatory T cells, revealing a promising mechanism of action.

SourceRice University·JournalClinical Cancer Research·TypeExperimental study·DateMay 12, 2026

USC researchers develop next-generation CAR T cells that show stronger, safer response in animal models

Researchers at USC's Keck School of Medicine have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer. The engineered CAR T cells may offer a way to more safely treat blood cancers and reduce the chance of relapse.

SourceKeck School of Medicine of USC·JournalScience Translational Medicine·TypeExperimental study·DateDec 10, 2025

Nasal therapeutic vaccine for treating cervical cancer

Researchers at Chiba University have developed a nasal therapeutic vaccine targeting E7 oncoprotein, which is produced by high-risk strains of HPV associated with cervical cancer. The vaccine triggers an immune response in the cervical mucosa, providing local protection against pathogens and foreign particles.

SourceChiba University·JournalScience Translational Medicine·TypeExperimental study·DateNov 12, 2025

Researchers at MIT develop new nanoparticles that stimulate the immune system to attack ovarian tumors

MIT researchers have developed new nanoparticles that deliver the immune-stimulating molecule IL-12 directly to ovarian tumors, eliciting a strong response and clearing tumors in over 80% of mice. This treatment combines with checkpoint inhibitors to launch an attack on cancer cells without causing side effects.

SourceMassachusetts Institute of Technology·JournalNature Materials·DateOct 31, 2025

Brain Network Disorders review highlights role of JAK2 pathway in worsening ischemic stroke outcomes

The JAK2-STAT3 pathway contributes to inflammation and injury after ischemic stroke. Targeting this pathway shows promise for reducing brain swelling, neuronal death, and improving recovery. Several inhibitors have been found effective in preclinical models, including Tyrphostin AG490, Ruxolitinib, and natural compounds like genistein.

SourceBrain Network Disorders Editorial Office·JournalBrain Network Disorders·TypeLiterature review·DateAug 4, 2025

Improving T cell responses to vaccines

Scientists have modified mRNA vaccines to include the cytokine IL-12, enhancing T cell responses and improving protection against diseases such as SARS-CoV-2, influenza, melanoma, and listeria infection. The study's findings suggest a promising approach to enhance immune stimulation against cancer and other pathogens.

SourceUniversity of Pennsylvania·JournalScience Immunology·TypeExperimental study·DateJun 6, 2025

Protein in the nose provides information about COPD

Researchers at Karolinska Institutet have developed a new method to diagnose COPD by analyzing protein levels in nasal lavage. The study found that elevated IL-26 levels can indicate an early phase of the disease, and may lead to new treatment strategies targeting this cytokine.

SourceKarolinska Institutet·JournalJournal of Allergy and Clinical Immunology·TypeExperimental study·DateMar 28, 2025

Researchers find missing link in autoimmune disorder

Scientists have identified a key component in launching immune activity and overactivity, providing a potential target for therapies that could prevent debilitating illnesses. The researchers discovered a protein in cells that spurs the release of infection-fighting molecules, which is essential for controlling the disease.

SourceWashU Medicine·JournalCell·TypeExperimental study·DateMar 18, 2025

Ultrasound-directed microbubbles could boost immune response against tumours, new Concordia research suggests

Concordia researchers propose a novel method using ultrasound-guided microbubbles to stimulate critical cytokine secretion in T cells, potentially re-activating them and increasing the release of proteins needed to fight cancer. The approach could complement existing treatments and improve outcomes.

SourceConcordia University·JournalFrontiers in Immunology·TypeExperimental study·DateJan 15, 2025

Shaking sensor continuously monitors inflammation

A new implantable device, inspired by a tree branch, uses DNA sensors to continuously monitor inflammation biomarkers in the body. The device accurately measures protein biomarkers of inflammation in diabetic rats and has potential applications for managing acute and chronic conditions.

SourceNorthwestern University·JournalScience·TypeExperimental study·DateDec 5, 2024

Fine particulate air pollution may play a role in adverse birth outcomes

A new study finds that fine particulate air pollution (PM2.5) exposure is associated with altered immune responses and increased inflammation in pregnant women, leading to adverse birth outcomes. The study highlights the importance of minimizing air pollution exposure in pregnant women to protect maternal and fetal health.

SourceHarvard T.H. Chan School of Public Health·JournalScience Advances·TypeExperimental study·DateNov 29, 2024

Zinc deficiency promotes Acinetobacter lung infection: study

A new study found that zinc deficiency promotes lung infection by Acinetobacter baumannii bacteria, which is a leading cause of ventilator-associated pneumonia. Blocking IL-13 prevented infection-associated death in an animal model, suggesting anti-IL-13 antibodies may protect against bacterial pneumonia in patients with zinc deficiency.

SourceVanderbilt University Medical Center·JournalNature Microbiology·TypeExperimental study·DateNov 15, 2024

Polymeric cloak stabilizes cytokine complex to generate tumor-targeted nanosuperagonist

A new method to construct protein complex-based therapeutics has been discovered using a polymer cloak, which stabilizes the delivery of protein complexes and enables tumor-targeted immunomodulation. The study presents an IL-15 nanosuperagonist with enhanced efficacy and specificity, promising a safer therapy for cancer treatment.

SourceInnovation Center of NanoMedicine·TypeExperimental study·DateOct 3, 2024

Unexpected immune response may hold key to long-term cancer remission

A new study published in Nature has found that the type 2 immune response is positively correlated with long-term cancer remission, contradicting previous theories that it promotes tumor growth. The research used samples from pioneering clinical trials and revealed a statistically significant correlation between type 2 immune factors a...

SourceEcole Polytechnique Fédérale de Lausanne·JournalNature·TypeExperimental study·DateSep 26, 2024

Dissolvable microneedle patch enables local delivery of immunomodulatory microparticles containing bifunctional molecules for periodontal tissue regeneration

Researchers developed a dissolvable microneedle patch to deliver immunomodulatory microparticles containing bifunctional molecules, such as azithromycin, to treat periodontitis. The patch demonstrated therapeutic outcomes by suppressing bacterial growth and modulating immune responses in both in vitro and in vivo studies.

Bacteria and keloids

Research found higher bacterial concentrations in keloid tissue, especially in deep layers, leading to increased inflammation and fibroblast production. Antibiotics and phage treatments may help reduce bacteria and improve treatment outcomes for keloids.

SourcePNAS Nexus·JournalPNAS Nexus·DateJul 30, 2024

Intermittent fasting shows promise in improving gut health, weight management

A new study highlights the benefits of intermittent fasting and protein-pacing on gut health, weight loss, and metabolic responses. Participants showed improved diversity of the gut microbiota, decreased symptoms of gastrointestinal problems, and increased beneficial microbes linked to a lean body type.

SourceArizona State University·JournalNature Communications·TypeRandomized controlled/clinical trial·DateMay 28, 2024

The Wim Hof method may reduce inflammation, per systematic review

The Wim Hof method has been found to increase epinephrine levels and decrease pro-inflammatory cytokines, indicating a potential anti-inflammatory response. However, its impact on exercise performance is less clear, with some studies showing benefits and others finding no significant difference.

SourcePLOS·JournalPLOS ONE·TypeSystematic review·DateMar 13, 2024

Key protein linked to immune disorders

Researchers found that STAP-1 plays a crucial role in activating T cells, which are white blood cells critical to defending against infections and maintaining overall health. The study suggests that STAP-1 may be involved in the development of immune disorders such as multiple sclerosis and asthma.

SourceHokkaido University·JournalThe Journal of Immunology·TypeExperimental study·DateMar 11, 2024

New cell therapy shows promise with ARDS patients

A new type of cell therapy has shown promising results in improving survival rates and reducing pneumonia among critically ill ARDS patients recovering from severe Covid-19. The invariant natural killer T (iNKT) cell therapy, known as agenT-797, triggered an anti-inflammatory response and activated anti-viral immunity.

SourceAnglia Ruskin University·JournalNature Communications·DateFeb 6, 2024

A new targeted treatment calms the cytokine storm

Researchers from Osaka University have discovered a novel treatment strategy for cytokine storm, a serious inflammatory syndrome triggered by an infection or severe burn. The new approach involves blocking IL-6 receptor signaling with a short-term antibody, minimizing treatment side effects and preventing vascular damage.

SourceOsaka University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateJan 17, 2024